Overall survival (OS) data, published simultaneously by the Journal of Clinical Oncology, 2 show the longest survival data ...
New KEYNOTE-B96 data add to previous results showing progression-free survival (PFS) and overall survival (OS) improvements ...
Climate change exacerbates health emergencies, affecting outcomes and healthcare access due to natural disasters like ...
Stephen Freedland, MD, of Cedars-Sinai, discussed enzalutamide and leuprolide's potential to improve overall survival without ...
Rebecca Dent, MD, MSc, deputy chief executive officer and senior consultant at the National Cancer Center in Singapore, ...
Roflumilast 0.05% cream, a phosphodiesterase 4 inhibitor, was approved by the FDA on October 6, having been specifically ...
Rates of diagnosis of peanut allergies and other food allergies mediated by immunoglobulin E (IgE) have decreased since guidelines were published that encouraged early exposure to peanuts in children, ...
Brensocatib effectively reduces NSP activity in bronchiectasis patients, with greater reductions observed in the 25-mg dose group compared to the 10-mg group.
Enfortumab vedotin and pembrolizumab with surgery significantly improve outcomes in cisplatin-ineligible MIBC patients, ...
Briers led off a group of speakers in an ESMO Quality of Life session on confronting sexual dysfunction after cancer care, which included a look at data from Europa UOMO on how treatment affects ...
In August, Zongertinib received FDA approval for previously treated HER2-mutant NSCLC. It now shows efficacy in first-line ...
Self-administration of rozanolixizumab, a neonatal Fc receptor blocker (FcRn) indicated for generalized myasthenia gravis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback